Literature DB >> 17287904

A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.

Chiaki Okuse1, Kayo Adachi, Yoshiki Katakura, Kotaro Matsunaga, Toshiya Ishii, Nobuyuki Matsumoto, Hiroshi Yotsuyanagi, Shiro Iino, Michihiro Suzuki, Fumio Itoh.   

Abstract

We present a case of deep venous thrombosis (DVT) during pegylated interferon (peg-IFN)-alpha2b plus ribavirin treatment of chronic hepatitis C (CHC). A 67-year-old man, who had been under treatment for hypertension and diabetes mellitus, was admitted to our hospital for peg-IFN-alpha2b plus ribavirin treatment for CHC. His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-alpha2b plus ribavirin treatment. He suffered from severe pain, flare, and edema in both of his lower legs 6 weeks after the initiation of peg-IFN-alpha2b plus ribavirin treatment. He was diagnosed as having DVT because of the presence of a thrombus in the right soleus vein by ultrasonography. Peg-IFN-alpha2b plus ribavirin treatment was discontinued because a causal relationship between DVT and peg-IFN-alpha2b plus ribavirin treatment was suspected. DVT was not observed and the symptoms in both of his legs were improved after the administration of warfarin potassium. Subsequently, DVT has not recurred, and he has remained HCV-RNA negative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287904     DOI: 10.1007/s00535-006-1910-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  30 in total

1.  Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

Authors:  S W Schalm; B E Hansen; L Chemello; A Bellobuono; J T Brouwer; O Weiland; L Cavalletto; R Schvarcz; G Ideo; A Alberti
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

2.  Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia.

Authors:  K Honda; A Ando; M Endo; K Shimizu; M Higashihara; K Nitta; H Nihei
Journal:  Am J Kidney Dis       Date:  1997-07       Impact factor: 8.860

3.  Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b.

Authors:  M Jadoul; H Piessevaux; A Ferrant; J P Cosyns; C van Ypersele de Strihou
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

4.  Thrombosis and recombinant interferon-alpha.

Authors:  J M Durand; N Quiles; G Kaplanski; J Soubeyrand
Journal:  Am J Med       Date:  1993-07       Impact factor: 4.965

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha.

Authors:  J Matsuda; N Saitoh; M Gotoh; K Gohchi; M Tsukamoto; S Syoji; K Miyake; M Yamanaka
Journal:  Am J Gastroenterol       Date:  1995-07       Impact factor: 10.864

7.  Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia.

Authors:  P Stratta; C Canavese; M Dogliani; A Thea; G Degani; L Mairone; A Vercellone
Journal:  Ren Fail       Date:  1993       Impact factor: 2.606

8.  Severe Raynaud's syndrome associated with interferon therapy. A case history.

Authors:  A Creutzig; M Freund
Journal:  Angiology       Date:  1996-02       Impact factor: 3.619

9.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

10.  Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.

Authors:  F Violi; D Ferro; S Basili; M Artini; G Valesini; M Levrero; C Cordova
Journal:  J Investig Med       Date:  1995-12       Impact factor: 2.895

View more
  2 in total

Review 1.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

2.  Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study.

Authors:  Chun-Cheng Wang; Chiz-Tzung Chang; Cheng-Li Lin; I-Ching Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.